Company intelligence
National Pharmaceutical Council
Policy-relevant research since 1953
About National Pharmaceutical Council
NPC serves patients and society with policy-relevant research on the value of patient access to innovative medicines and the importance of scientific advancement. We envision a world where advances in medicine are accessible to patients, valued by society, and sustainably reimbursed by payers to ensure continued innovation. We provide the evidence to bolster the case for the value of innovation through our policy-relevant research. NPC informs policy discussions in the media, in Congressional testimony, and through leading voices sharing our research about the future of innovative medicine and patient access.
Verified activity
Signals from National Pharmaceutical Council
7 published signals
Research & Knowledge
National Pharmaceutical Council published a guide explaining the risks of Upper Payment Limit (UPL) implementation, what's at stake, and the current landscape.
Reported by National Pharmaceutical Council
Presence & Recognition
National Pharmaceutical Council President and CEO John O'Brien will join Christie Bloomquist of Boehringer Ingelheim, Samaneh K. of Zealand Pharma, and Ryan Urgo of Eli Lilly and Company for a conversation on
Reported by National Pharmaceutical Council
Presence & Recognition
National Pharmaceutical Council President and CEO John O'Brien will join Chris Pernie of Novo Nordisk, Jen Dial of Roche Diagnostics USA, Christian Emering of Harmony Biosciences, and Ryan Kuresman of GCI Health for the panel session at FiercePharmaWeek in Philadelphia on Tuesday, September 15.
Reported by National Pharmaceutical Council
Presence & Recognition
National Pharmaceutical Council Chief Communications Officer Michael Pratt will moderate a session with Marisa Sharkey, MA, APR of Harmony Biosciences, Kelley Yoder of Ruder Finn, Ned Ehrbar of Merck, and Robert Thompson of AbbVie on strategies to
Reported by National Pharmaceutical Council
Legal & Regulatory
National Pharmaceutical Council achieved Great Place To Work Certification for a third consecutive year.
Reported by John O'Brien
Presence & Recognition
National Pharmaceutical Council announced that NPC This Week features sessions on navigating the CAR T-cell treatment journey, the cost of 340B to states, Florida PBM lawsuits, and more.
Reported by National Pharmaceutical Council
Research & Knowledge
National Pharmaceutical Council published a new Policy & Evidence Brief titled The CAR T-Cell Patient & Caregiver Odyssey: Navigating the Journey to Treatment in an Evolving Access Environment, finding that most eligible patients still go untreated, time to treatment matters, delays fall unequally, and coordination across stakeholders is needed.
Reported by National Pharmaceutical Council